Few studies have investigated sexual disorders in men with advanced KC treated with molecular targeted therapy (MTT); antiangiogenic therapies (sunitinib, sorafenib, and bevacizumab) and mTOR inhibitors (temsirolimus and everolimus) caused a decline of erectile function scores and sexual activity after treatment ( 66 , 67 ). This evidence concerns the gene MTOR and sexual disorder.